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Abstract:
Homocysteine, a metabolite from methionine breakdown, can have detrimental effects to
multiple systems in the human body. Methionine is naturally acquired from diet and if too much
is consumed, as in diets with high red meats, the metabolic system becomes overloaded leading
to elevated blood levels of homocysteine. This condition is called hyperhomocysteinemia (Hcy).
Hyperhomocysteinemia is also related to aging and several genetic factors which ensure its
proper regulation. More importantly, hyperhomocysteinemia has been shown as a risk factor to
numerous disease states including cardiovascular disease and in neuropsychiatric illness. With
respect to cardiovascular pathology, it has been found from the results of 80 clinical studies
which sampled around 10,000 patients that elevated levels of homocysteine is linked with
increased cardiovascular mortality rates. Along with Hcy’s effect on the cardiovascular system it
has also been shown to induce neurological disorders in the form of neural tube defects, mental
disorders, and cognitive impairment. From the literature I will explain plausible routes that Hcy
affects vascular function and from data acquired during research conducted at the University of
Louisville I will show it’s implication in memory impairment. The data also includes the
possible treatment of sodium hydrogen sulfide to alleviate Hcy’s neurological effects.

Key Words: homocysteine, hyperhomocysteinemia, thiolactone, endothelium, oxidative stress,
neurotoxicity, mitochondria, cognitive impairment, thrombosis, arteriosclerotic lesions, blood
pressure

ii

Table of Contents
I.

What is Homocysteine? - 1
a. Metabolism/ mechanism

II.

Common Causes of Alternating Homocysteine Levels- 3
a. Genes
b. Diet/ exercise
c. Age
d. Gender
e. Smoking

III.

Important Forms of Homocysteine in the Blood- 7
a. Protein bound
b. Free oxidized
c. Free reduced

IV.

Homocysteine and Endothelial Dysfunction- 11
a. Blood pressure
b. Platelet Aggregation
c. MMP activation and monocyte adhesion
d. Smooth muscle cell proliferation

V.

Homocysteine, the Blood Brain Barrier, and Memory Impairment- 20
a. Brief description of University of Louisville project
b. Some Results of the Project

VI.

Conclusion- 31

iii

List of Figures and Tables
Figure 1: Simple Methionine Metabolism- 2
Figure 2: Simple Homocysteine Metabolism- 3
Table 1: Homocysteine Levels between Non-Smokers and Smokers- 7
Table 2: Relative Concentrations of Blood Forms of Homocysteine- 8
Figure 3: Formation of Arterial Blockage and Thrombotic Events- 18
Figure 4: Image of Increased Smooth Muscle Proliferation in Vessel- 20
Table 3: Recognition Test Results- 23
Table 4: Depression Swim Test Results- 24
Figure 5: Hypothesis for Homocysteine’s Effects on Memory- 25
Table 5: Blood Brain Barrier Permeability Test- 26
Table 6: Results of MMP PcR and Western Blots- 27
Table 7: Results of MMP Activity by Zymography- 28
Table 8: Slide Staining to Show Astrocyte Retraction and Vessel Integrity- 28
Table 9: Result of Intracellular Calcium Test- 30
Table 10: Results of Autophagy PcR- 31
Table 11: Results of Autophagy Western Blot- 31

iv

Acknowledgements

The author would like to thank his mentor, Dr. Martin Brock, for his help and support in this
project and his carefulness to teach instead of tell.

Thank you also to the friendly staff and research personnel at the University of Louisville
Preston Street Research Campus, they have taught different cultures as well as different
techniques of scientific investigation.

And lastly, he would like to the directors of Eastern Kentucky University’s Honors programs
during his thesis process, Dr. Linda Frost and Dr. David Coleman, for their support as well as
organization of several research conferences and trips.

I: What is Homocysteine?:
Neurovascular and cardiovascular diseases are becoming increasingly prevalent as
the population ages. Many of these diseases, including Alzheimer’s, stroke, Parkinson’s,
depression, and dementia, have a link to elevated levels of homocysteine in the blood
[1,2,3]. From the prevalence of these diseases, homocysteine’s negative effects need to be
examined further. Homocysteine itself is a sulfur-containing, non-proteinogenic amino
acid that is a by-product of normal methionine metabolism [4].
Methionine is one of two sulfur containing essential amino acids and plays an
important role in the proper function of many proteins. Methionine is normally consumed
in high levels by eating red meats (0.843g/100g) and eggs (2.48g/100g), as well as a
variety of nuts, fish, and poultry [5]. Because methionine contains sulfur it is prone to
oxidation, but generally it is stabilized by hydrophobic interactions and is not highly
nucleophilic like its sister molecule cysteine. Methionine is normally metabolized
properly in most people, but the pathway seems to be less effective with aging and also
with epigenetic factors such as poor diet and exercise [6]. The pathway and subsequent
enzymes involved are shown below [Figure 1].

Kyles 2

Figure 1: Shown above is the basic methionine metabolic pathway. B12 (1) and folic acid (2) play key roles
in proper breakdown. Under proper conditions homocysteine is converted back to methionine due to its
essential nature.

The alteration of the methionine pathway can lead to a buildup of homocysteine
within the blood above normal concentrations, which is termed hyperhomocysteinemia.
Normally, homocysteine is metabolized into two primary fates: it is either
transmethylated back to methionine to assist the folate cycle or is transulfanated into
cystathionine by CBS.
The transmethylation pathway requires cyanocobalamin (B12), folate and the
enzyme 5,10- methylenetetrahydrofolate reductase (MTHFR). Homocysteine acquires a
methyl group from N-5-methyltetrahydrofolate (5-methyl THF) which is an intermediary
in the folate cycle that occurs in all tissue and is dependent on cyanocobalamin (B12)
[29]. After acquiring a methyl group homocysteine is converted into tetrahydrofolate
(THF) and methionine by methionine synthase (MS) and cyanocobalamin (B12) [29].
There is another way homocysteine is remethylated but this primarily occurs in the liver
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and kidneys with betaine donating a methyl group by ways of betaine homocysteine Smethyltransferase into dimethylglycine [30].
The transulfanation pathway entails the enzyme cystathionine beta-synthase
(CBS) and pyridoxine (B6). The initial step in this pathway is the union of homocysteine
and serine, catalyzed by cystathionine beta synthase, creating cystathionine [30]. For
CBS, pyridoxine (B6) is an essential cofactor explaining increase of homocysteine with
certain diets. Abnormalities of this pathway can also influence remethylation by stressing
its capacity. When the folate cycle is overwhelmed it uses S-Adenosylmethioine (SAM)
to re-convert back to methionine. In cases where methionine is concentrated, CBS and
MTHFR are unavailable or ineffective, the system is overloaded leading to an
accumulation of homocysteine. The basic metabolism of homocysteine is shown below
[Figure 2].

Figure 2

II: Common Causes of Alternating Homocysteine Levels:
The progressions of homocysteine concentrations in human blood are as followsnormal: 8-15 μmol/L, moderate: 15-30 μmol/L, elevated: 30-100 μmol/L, and high: 100>
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μmol/L [7]. As previously stated these levels can vary upon several factors including:
genetic factors, diet and exercise, age, gender, and smoking.
Genetic factors can lead to the elevation of plasma homocysteine through the
mutation or knockout of several enzymes. Children whose parents have had a history of
cardiovascular disease tend to have higher levels of plasma homocysteine levels leading
to the conclusion of inheritance. This increased risk is attributed to two main genetic
factors: the alteration of the CBS and MTHFR genes. CBS, as previously mentioned, is
essential for proper homocysteine metabolism. Homozygosity of for CBS deficiency is
rare (1/300,000 births) and similarly, heterozygosity for CBS occurs in less than 1% of
the population [11]. Homozygosity of CBS causes severe hyperhomocystemia and CBS
heterozygosity causes mild hyperhomocystemia and is why CBS +/- knockout mice are
common experimental models.
Methyltetrahydrofolate reductase (MTHR) is also important to proper reconversion of homocysteine to methionine and its modification can cause increased
homocysteine levels as well. The C677T mutation of the MTHFR gene is more common
than CBS issues and occurs in 35-39% of the Caucasian North American population and
leads to a predisposition towards vitamin deficiencies and elevated homocysteine levels
[12]. The C677T homozygous mutation occurs in 10-15% of the population and leads to
a threefold increase in cardiovascular risk. The heterozygous mutation of C677T is more
prevalent at 22-25% of the population, but only leads to moderate increases in plasma
homocysteine levels in individuals lacking proper diet [12, 13].
Diet and exercise also play a role in elevated homocysteine levels. Diet seems to
play a significant role in managing homocysteine levels while the impact of exercise is
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less clear. Increased intake of foods containing higher levels of folic acid,
cyanocobalamin (B12), and pyridoxine (B6) will reduce blood levels of homocysteine
regardless of pre-diet levels [11, 14].
Dr. Kilmer McCully MD in his book, The Homocysteine Revolution, presents a
strong argument for proper diet in reducing both homocysteine and prominence of
vascular issues. He argues that in developed countries diets are full of processed foods
which knowingly are short in pyridoxine (B6) and folic acid due to their sensitively
towards destruction in food processing; for example in the refining and preservation of
wheat into white flour, 50-90% of pyridoxine (B6) is destroyed, and in the canning of
meats and fish the loss ranges from 40-50% [60]. On the opposite end however, fruits and
vegetables are common choices that contain high folate levels and have been shown to
offer protection against the onset of cardiovascular disease [15].
For cyanocobalamin (B12) and pyridoxine (B6), it has been observed that elderly
populations are usually lacking in these vitamins due to poor diets and failure to absorb
them properly which adds to their apparent heightened age specific homocysteine levels
[16]. The combination of these three nutrients is essential for proper managing of
homocysteine levels [17]. In fact, cyanocobalamin (B12) is required for methionine
synthase to function properly. However it is important to note that the decrease in
homocysteine levels does not repair the damage caused, nor does the decrease prevent
recurrence of cardiovascular or neurovascular events- its control simply seems to prevent
issues from arising [19,60]. On the contrary to the effects of proper folate and pyridoxine
(B6) and cyanocobalamin (B12) consumption, some certain dietary foods can lead to a
marked accumulation of homocysteine. Increased consumption of coffee, ethanol, red
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meats, fish, chicken, cheese, and eggs as opposed to plant protein sources can cause
increased homocysteine levels [18].
The relationship between increased exercise and homocysteine levels is widely
debated, but important to mention when researching homocysteine and its effects. The
results of numerous exercise studies seems to indicate that chronic, higher intensity
exercise speeds up the metabolism of methionine to homocysteine leading to increased
levels in individuals. Similarly individuals who had sedimentary lifestyles before
beginning a moderate exercise regimen composed of walking for approximately 30
minutes, several times a week, reported having lower homocysteine levels as compared to
the beginning of the trial [18]. These general studies however should be taken lightly in
that they fail to encompass a number of factors that could influence homocysteine levels
such as: stress, general health to begin with, accuracy of exercise reporting, creatinine
levels, and many more. Besides the inconsistency in exercise effectiveness in moderating
homocysteine levels, numerous reports support the idea that exercise improves both
cardiovascular and nervous system function as a whole.
Gender also plays a role in blood concentrations of homocysteine. From several
studies, premenopausal women are known to be protected from coronary disease
compared to postmenopausal women suggesting the role of estrogen in vascular health
[24]. Estrogen and homocysteine studies suggest that higher estrogen status “is associated
with lower homocysteine levels independent of nutrition and muscle mass and may
explain the reported male-female difference in total homocysteine concentration” [20,21].
Estrogen levels also seem to play a role in increased folate utilization, which would assist
the remethylation of homocysteine [22]. From the differing hormone levels, the 5-8 fold
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risk of coronary artery disease of males aged 25-55 years compared to females may be
explained by the fluctuating homocysteine levels associated with estrogen. The difference
in levels may also be associated with higher muscle mass in men. The formation of
muscles is associated with increased creatine/ creatinine synthesis which runs
simultaneously to homocysteine formation [33].
The last major contributor to homocysteine levels is smoking. Smoking
exacerbates the effects of homocysteine in that it also acts independently from other
vascular risk factors. It is a well-known fact that people who smoke have a higher
occurrence of a number of cardiovascular and neurovascular issues and it comes to no
surprise that this risk is parallel to their overall homocysteine levels. Smoking has also
been shown to change plasma chemistry affecting the thiol redox balance and also may
inhibit methionine synthase [34]. A comparison study’s results between smokers and
non- smokers is shown below [23] [Table 1]. However it is important to note that this
study did not base line for diet, but the p-values for the results suggest significance
outside of this influence.




  





  



Homocysteine, µmol/L

18.46

12.75

0.04

Folic acid, nmol/L

4.30

4.45

0.56

Vitamin B12, pmol/L

363.94

407.45

<10-7

Table 1: Comparison between non-smokers and smokers with levels of homocysteine, folic acid, and vitamin B12 represented.
The results were obtained from Mohamed Fadhel Najjar, et al. "Effect of Cigarette Smoking on Plasma Homocysteine
Concentrations."
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III: Important Forms of Homocysteine in the Blood:
The sources listed above all provide for increases in homocysteine levels. Once
concentrations of homocysteine overwhelm the mechanisms meant to keep it in check,
homocysteine can take several damaging forms. These main forms are protein bound,
free oxidized, and free reduced, and together encompass total homocysteine levels [Table
2].

Table 2: The three main classes of plasma homocysteine. Relative to 12 µmol/L obtained from Mudd SH, Finkelstein JD,
Refsum H, Ueland PM, Malinow MR, Lentz SR, et al. Homocysteine and its disulfide derivatives: a suggested consensus
terminology. Arterioscler Thromb Vasc Biol 2000;20: 1704-1706.

The most common form of homocysteine found in plasma is when it is bound to
proteins such as albumin. It also can bind to other proteins such as ɣ-globulin, αglycoprotein, transthyretin, and high-density lipoproteins, but in lessening levels. The
combination of these constitutes approximately 80% of total plasma levels [27, 28].
Albumin is particularly prone to homocysteine due to a free cysteine residue at an Nterminal position where oxidation with homocysteine’s sulphur can occur. These proteinhomocysteine compounds are termed S- Homocysteinyl-Protein and are generally
considered to be biologically unreactive [27]; however this process of
homocysteinylation can alter metabolizing agents such as homocysteine’s own
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endogenous metabolizing enzyme cystathionine γ-lyase which is responsible, among
other things, for the catalysis of L-cystine to hydrogen sulfide [42]. The alteration and
substrate inhibition of this enzyme may limit the supply of the potent anti-oxidizing agent
and vaso-relaxing agent hydrogen sulfide, a subject we discuss in section V [44].
The next form is free oxidized homocysteine which occurs when two
homocysteine molecules interact forming a new homocystine compound or when
homocysteine interacts with cysteine forming a homocysteine-cysteine molecule. These
compounds are formed due the chemical reactivity of homocysteine at physiological pH
causing the thiols to form a bridge creating the homodimer homocystine or a
homocysteine bound to a cysteine [28]. The reaction is shown in the following
generalized formula: 2 R-SH = R-SS-R + 2H+ + 2e-. These free electrons can then react
singly or in pairs in reducing oxygen; the product is superoxide if one electron reacts and
a peroxide if 2 elections react. Oxidized homocysteine is relatively reactive due to
oxidative stress, but the free reduced form of homocysteine is the most reactive of them
all.
The last major form of homocysteine in the plasma is free (reduced)
homocysteine and it exists in less than 2% of total levels [28]. There is evidence
suggesting that the free thiol form of homocysteine is more harmful than the protein
bound and the disulfide species described earlier [28]. Normally free homocysteine binds
to proteins or interacts with itself or cysteine but some is left over. The left over is termed
reduced homocysteine and has a highly reactive free thiol group that can participate in
redox reactions [28,29]. Several studies have shown that this free thiol is associated with
endothelial dysfunction in humans while the protein and disulfide forms did not
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contribute significantly [31, 32]. The free reduced form is mainly oxidized to the
disulfide forms. However some of this free form is converted into homocysteine’s
thiolactone [32].

Homocysteine thiolactone

Homocysteine

Homocysteine’s thiolactone is related to serum levels of free reduced
homocysteine; homocysteine’s thiolactone is synthesized by methionyl-tRNA synthetase
(MetRS) in human endothelial cells, as well as several others such as fibroblasts and
breast cancer cells [37]. It is important to note that homocysteine’s thiolactone level of
0.2 nM in normal individuals increases to 14.4 nM and 11.8 nM in CBS and MTHFR
mutated patients respectively [36]. Although, as previously mentioned, patients with
CBS/ MTHFR issues show elevated total homocysteine levels, the increase of thiolactone
occurs significantly outside of the total increase showing its importance in vascular issues
associated with hyperhomocysteinemia [36]. Because free reduced homocysteine and its
thiolactone are related, thiolactone proves to be highly reactive and may provide a
mechanism of hyperhomocysteinemia’s vascular effects and will be discussed later
[36,37].
As presented, numerous meta-analysis and cohort studies have shown a link
between homocysteine and increased vascular risks. There are many sources of increased
homocysteine levels, ranging from diet to genetics, and it is clear that these increased
concentrations summate towards the deregulation of proper vascular and nervous
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function. In this study we aim to show the negative effects of homocysteine through the
vascular system first and then in its apparent implication in memory by experiment.

IV: Homocysteine and Endothelial Dysfunction:
The first reports linking plasma levels of homocysteine to cardiovascular risks
were published on mentally retarded children in 1962. Physicians initially noticed high
concentrations of homocysteine in the children’s urine, a condition called
homocystinuria, and in later years found the gene coding for cysteine-beta synthase
(CBS) to be lacking in many cases [8]. Mudd and colleagues described four major
hallmarks of the CBS deficient patients: ocular lens dislocation, skeletal abnormalities,
differing degrees of mental retardation, and thromboembolic disease which was often the
cause of their premature deaths [50]. Also Mudd, and later McCully documented
widespread vascular atherosclerotic lesions in autopsies of hyperhomocysteinemic
patients [50]. However, at the time many believed that hyperhomocysteinemia simply
blended in with other risk factors such as HDL and LDL in causing vascular issues; but
we know now this is not entirely the case.
Upon further investigation it was found that children with defects in CBS, and
subsequently high levels of circulating homocysteine, frequently had thromboembolic
events. This finding was later re-confirmed by Wilcken and Wilcken in 1976 when they
linked altered homocysteine metabolism to coronary artery issues [9]. In a landmark
study in 1985, Mudd and colleagues studied 600 patients and their response to high doses
to pyridoxine (B6) to test if the reduction of homocysteine was parallel to reduced
vascular problems; they found risk was significantly reduced in the treatment population
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[51]. Also the previously noted concern for homocysteine masking by other risk factors
was disproven by the meta-analysis of Boushey et al in 1995, and in later studies of the
2000s which concluded that the association between plasma homocysteine levels and
cardiovascular problems remains strong even after adjustment for other risk factors
[10,67].
From the compiled information linking homocysteine to cardiovascular issues the
question of how does homocysteine specifically act on the cardiovascular system arises.
To understand the routes of action a brief review of cardiovascular components is needed.
The cardiovascular system is essentially composed of the heart, the arteries and veins,
and the blood. All of these parts work in cooperation to create circulation. The functional
unit of each of these components is primarily the vascular endothelial cell. Vascular
endothelial cells provide lining for capillaries, veins and arteries, and the thick walls of
the heart and their upkeep is essential to a healthy cardiovascular system. Congruently the
majority of cardiovascular problems arise from issues in endothelial lining. For the
purpose of this report we will limit the discussion to how homocysteine affects the
endothelial lining in explaining its negative impacts.
The major route of homocysteine acting on endothelial cells is widely contested,
but recently increased evidence has confirmed its importance. In this section it is
important to note that many of homocysteine’s effects, especially in the formation of
atherosclerosis, can be activated by other means besides a lining breech [69]. In this
article we will entertain that homocysteine effects the endothelial vessel lining in four
major ways: by increasing blood pressure, by activating platelet aggregation, by oxidative

Kyles 13
stress release and MMP activation by monocyte adhesion, and by inducing smooth
muscle proliferation.
The first route homocysteine can act on the endothelial lining is by increasing
blood pressure. In the cardiovascular system pressures differ greatly with each heartbeat
as expressed by the systolic (maximum) and diastolic (minimum) readings of a blood
pressure cuff. The endothelial lining is expected to undergo functional adaptations to
accompany the pressure load. The development of blood pressure issues arises when this
adaptation is abused and elasticity is lost or structural components of the endothelium are
compromised providing resistance. These developments occur 95% of the time from
idiopathic or multifactorial sources [43]. Because blood pressure can compromise and
activate a plethora of endothelial issues, it is important to note how homocysteine may
play a role in its increase.
Homocysteine has been shown to increase blood pressure by the “Hordaland
Study” in which 16,000 people aging from 40-67 years old with no history of
hypertension were tested and homocysteine levels were found to be positively correlated
with pressure levels [45]. Several mechanisms have been proposed to explain this find
including: increased vascular hypertrophy (enlargement of endothelial cells), reduced
availability of endothelial nitrous oxide and H2S (vaso-dilating agents), increased
vascular smooth muscle cell proliferation (leading to tightness), antagonizing the smooth
muscle cells (thickness/ vasoconstriction from angiotensin), increased intimal-medial
thickness by amplified levels of collagen impairing vascular compliance (less elasticity),
and increased intracellular calcium levels affecting vascular muscle cell tension (muscles
squeeze vessels) [42]. Much research needs to be done elucidating the exact mechanisms
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of each. The rise in tension and narrowing of the vessels caused by homocysteine and
increased blood pressure can lead to an increase in thrombotic events such as stroke and
heart attack.
The second route homocysteine can act on the cardiovascular system is through
increased platelet aggregation. This theory of homocysteine’s influence on clot formation
was first proposed by McDonald et al. in 1964 when he noticed an increased adhesion of
homocysteine’s platelets on a glass surface [51, pg 415]. As previously mentioned
homocysteine can become autoxidized in the blood forming dimers and also can be
bonded to proteins. It can also be converted into a thiolactone [25]. This molecule will
become important with its interactions with platelets.
Platelets, also known as thrombocytes, are involved in the clotting mechanism.
Individually platelets contain integrin molecules, as well as many other receptors, on their
surfaces. One of these integrin surface proteins is glycoprotein IIb/IIIa (integrin αIIbβ3)
[38]. This integrin is the most abundant platelet adhesion molecule and is found in a
density of approximately 80,000 receptors per platelet [52]. During vessel injury and clot
formation this receptor’s job is to show affinity and bind to fibrinogen and also to
activate von Willebrand factors which exponentially increase the “stickiness” of a platelet
aggregate [46]. These factors also increase the platelets affinity to exposed collagen on
the endothelium which rapidly occurs in injuries where the basal collagenous membrane
of the vessel is exposed.
In patients with hyperhomocysteinemia, it has been shown that homocysteine and
its thiolactone both antagonize integrin αIIbβ3 changing its confirmation permitting
binding of its ligand, fibrinogen [38]. This primarily occurs by homocysteine’s
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thiolactone interacting with a cysteine group within integrin inadvertently activating it
[52]. It is interesting to note that integrin αIIbβ3 has been shown to have thiol isomerase
activity, which in normal processes acts in appropriately changing confirmation to an
active state, so it is plausible that thiolactone could interact to inadvertently activate this
adhesion receptor [52,53]. The binding of integrin αIIbβ3 to fibrinogen creates a cross
bridge to another platelet causing the beginnings of a clot [39]. This ligand binding in
turn activates alpha granules inside each platelet, which release p-selectins that signal
other platelets to become more “sticky” [38, 39, 40]. Several studies show that increased
levels of homocysteine and its thiolactone augment platelet activation causing the
platelets to form clots more readily [38]. Not surprisingly in these studies thiolactone was
found to be more effective in modulating platelet adhesion [38]. If these clots reach sizes
of arterial blockage, heart attacks and strokes can occur by putting stress on weak spots in
the endothelial lining of vessels, especially in a capillary/ micro vessel setting, as we will
see in the microvasculature of the brain later on. This stress is a topic that is essential in
understanding homocysteine’s negative vascular effects and also in its neuronal
pathology.
As previously mentioned, blood pressure is markedly increased in
hyperhomocysteinemic patients which is caused by an increase in collagen deposition in
the extra-cellular matrix among other factors [47]. This increase in endothelial tension
can cause atherosclerotic injuries at bifurcated vessels where pressure is the highest.
These micro lesions on the endothelium lining then expose collagen and subsequently
create a “rough” patch on the otherwise smooth lining. This rough spot creates a perfect
place for the platelet’s increased affinity for other platelets, collagen, and stickiness to
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combine. This complex of platelet’s can then aggregate creating thrombotic and
atherosclerotic events leading to increased risks of heart attacks and stroke.
The third route to be discussed on homocysteine’s interaction with endothelial
cells is autoxidation and MMP activation. Homocysteine’s autoxidation at physiological
pH was previously explained through its homodimer formation and interactions with
cysteine to form a homocysteine- cysteine molecule [28]. This creates either a superoxide
or peroxide depending on how many electrons react with oxygen. The increased
oxidative stress on endothelial cells induces the expression of several matrix
metalloproteinases by mimicking an injurious environment.
Matrix metalloproteinases are a family of endopeptidases that break down amino
acids within proteins and can be thought of as protein “scissors”. Their primary job is to
regulate the extracellular matrix, which in terms of endothelial cells, is the structural
support that keeps vessels healthy. In events where these proteases are overly activated
there is a marked decrease in vascular wall integrity [61]. Within the endothelial
extracellular matrix two MMPs are of importance; these are MMP-2 and MMP-9. The
reason that these two MMPs are of high importance is because they are the only ones
capable of degrading collagen type IV and are classified as gelitanases which allow for
easier determination of their activity in vitro by zymography. This interaction with
collagen is especially important in capillaries and micro-vessels, a subject we will discuss
later in relation to neuron microvascular health.
In hyperhomocysteinemia these two MMPs have been shown to interact with
endothelial tight junction proteins in capillary settings and increase permeability and
leakage [48]. Also in knockout studies MMP-2 and MMP-9 have been implemented in
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cardiac rupture after myocardial infarctions which suggests their role in major vessel
structure and the creation of new vessels as well [49]. However, much about MMP
activation in hyperhomocysteinemic events is not fully understood. There is some
evidence supporting a hypothesis of MMP activation besides just saying, “reactive
oxidative species activate MMPs,” which is a common phrase in oxidative studies of
hyperhomocysteinemia. The activation of these MMPs may be generated by vascular cell
adhesion protein (VCAM-1) and intercellular adhesion molecule (ICAM-1) being upregulated in hyperhomocysteinemia leading to increased monocyte and leukocyte binding
[54, 55].
In normal individuals the site of endothelial damage is quickly relieved and
suppressed to prevent vascular issues from arising. One step in this process is to help
reduce the chance of infection by increasing the injured area’s affinity for monocytes. As
previously mentioned, the blood is always circulating with each heartbeat and the injured
site needs some way to stop these monocytes from simply rolling away- the answer is up
regulation of the VCAM and ICAM receptors [39, 56]. In hyperhomocysteinemia, the
vessels are stressed from increased pressure, reactive oxidative species, reduction of
bioavailable NO, and increased cytokine concentrations which can mimic an inflamed
injurious environment [54, 56, 62]. Due to this increased stress several studies have
reported a drastic up-regulation in VCAM and ICAM and subsequently an increased
binding of monocytes [54, 55, 57].
Upon binding to the up-regulated VCAM and ICAM receptors, the monocyte
undergoes diapedesis (intake during inflammation) into the sub-endothelial space where
they convert into macrophages. During this process there is evidence that the binding of
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monocytes to VCAM and ICAM stimulates their NAPDH oxidases to undergo a
“respiratory burst” which is intended to destroy any pathogens around [56, 58, 59].
Normally this “burst” of reactive peroxidases and superoxides are kept in check by
powerful antioxidants, but in a non-injured vessel who’s antioxidant systems are already
compromised by the unavailability of NO (nitrous oxide) and possibly GSH
(gluthionine), along with the increased affinity and occurrence of monocyte adhesion
could lead to a situation where reactive oxidative species are increasingly prevalent. Also
the activation of these cells leads to a release cytokines, chemokines, and growth factors
which gives rise to an inflammatory environment [62]. This increase of reactive species
would cause the activation of MMP-9 and MMP-2 to begin remodeling the endothelial
extracellular matrix, basal membranes, and tight junction proteins which can cause
increased permeability of LDL cholesterol to enter the sub-endothelial level forming a
“bubble” in the intima as shown below [Figure 3].

Figure 3: Formation of arterial blockage and thrombotic events. The endothelial is compromised leading to monocyte diapedesis and
macrophage conversion by LDL into foam cells freeing cholesterol and increasing fatty buildup. Daniel J. Rader & Alan Daugherty
Nature 451, 904-913(21 February 2008)
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The fourth major route homocysteine interacts with the endothelial lining to be
discussed in this report deals with smooth muscle cell proliferation. From studies of
atherosclerosis it was found that often smooth muscle cells migrate to the subendothelium in regions of vascular injury [62]. Normally these cells circulate as
progenitor cells and are activated by platelet derived growth factor which can be found in
alpha granules distributed by activated platelets, which as explained earlier, can be
induced by homocysteine’s interactions with integrin [38, 65]. This migration is also
followed by a marked increase in their proliferation in hyperhomocysteinemic conditions
[64]. This increased proliferation creates increased amounts of layers thus decreasing the
size of the vascular lumen creating an environment ripe for atheroma, which is the
swelling of artery walls and accumulation of plaque [60].
The route of this activation is still currently being investigated and involves many
key players. However it is clear that homocysteine can induce connective tissue growth
factor (CTGF), a potent stimulator of smooth muscle proliferation in the vascular intima.
Several pathways in hyperhomocysteinemic conditions lead to the up-regulation of
CTGF. These up-regulations seem to be caused by a possible stimulation of PKC by
homocysteine and also by the release of ROS, especially H2O2 and its apparent direct
activation of Janus Kinase 2 and 3 (JAK2/JAK3) which leads to CTGF and cytokine
release [66,68]. Both of these pathways are shown to be up-regulated in
hyperhomocysteinemic conditions and cause an increase in the “layers” of muscle cells
and collagen deposition which affect proper vessel structure as shown below in figure 4.
The image below represents smooth muscle proliferation after injury and shows the result
of “increased layers.”
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Figure 4: Pictures of mice arteries comparing smooth muscle proliferation after a denudation injury. [A] is the injured vessel [B]
normal. These images are to show vessel narrowing by SMC proliferation. Findeisen, Hannes M, et al. "Epigenetic Regulation of
Vascular Smooth Muscle Cell Proliferation.”

The four routes of homocysteine’s interactions with the endothelial cell can affect
both its proper function and structure. In summary these were discussed in four routes:
increased blood pressure, activated platelet aggregation, oxidative stress release and
MMP activation by monocyte adhesion, and smooth muscle proliferation. However when
dealing with homocysteine in the neuron and memory impairment the vessels are merely
half the picture, the other half is the neuron itself and through research conducted at the
University of Louisville the intricate relationship between micro-vessels, the neuron, and
their role in memory was explored.

V: Homocysteine, the Blood Brain Barrier, and Memory ImpairmentUniversity of Louisville Summer Research Program:
Homocysteine and its effect on vascular function are not limited to the endothelial
cells, but can also be implicated in proper neuronal function. In a review of neurological
diseases it was found that homocysteine was elevated when cognitive decline occurred
[70]. Initially an increase of homocysteine levels was reported by Regland and colleagues
in patients with dementia in 1990 [70, 71]; since then, the link has become clearer with an
increased interest in the research of elderly conditions such as Alzheimer’s and
Parkinson’s [72]. In one study a cohort of 321 men were assessed for diet, folate, B
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vitamins, and homocysteine over the course of 3 years with increments of examination
through the Mini-Mental State Examination; the group found that there was a strong link
between a decreased cognitive score and increased homocysteine levels and interestingly,
they also found that folate intake seemed to offset this decline [73]. Along with a plethora
of other studies, the link between homocysteine and its metabolism has been connected to
cognitive impairment. The mechanism of this supposed decline is more appropriately
addressed through the memory center of the brain.
The role of the hippocampus was discovered by the famous case of Henry
Molaison and his surgical removal of the region to alleviate seizures. His surgery
occurred in 1953 and removed most of his hippocampus and surrounding tissues. After
his surgery scientists found he suffered anterograde amnesia, which is the inability to
form new memories, and moderate retrograde amnesia, which deals with past memories
[74]. This finding started an intense rise of memory related research and also serves as a
prime starting point in investigating homocysteine’s apparent impact on memory
formation.
During research conducted at the University of Louisville’s Cardiovascular and
Physiology Summer Program for Undergraduate Students 2013, the role of homocysteine
in cognitive decline and the possible treatment with hydrogen sulfide was investigated.
This paper will give a brief explanation of some of the findings during the three month
experiment, but in order to understand the experiment more fully a brief summary of
what was done is in order.
In the experiment there were six treatment groups (mice) that were injected with
the following respective compounds intracranially at the start of the trial: artificial
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cerebrospinal fluid (aCSF), homocysteine (Hcy), homocysteine+ NaHS, homocysteine+
MK801, MK801 per se, and NaHS per se. The NaHS (sodium hydrogen sulfide) and
MK801 treatments were continued intraperitoneally for a 7 day period. After the 7 day
period was finished, the animals were removed and subjected to novel object tests for
memory, depression tests, tail cuff blood pressure tests, Doppler fluorometry tests, and
finally sacrificed for immunohistochemistry tests such as western blots, semi-quantitative
PcR, zymography, and slide tissue staining.
In our particular project we set out to confirm the reported effects homocysteine
had on the hippocampus as well as to determine if hydrogen sulfide could attenuate the
negative effects through mitigation of the NMDA receptor as well as reduce the oxidative
stress and tension on the micro-vessels through its strong antioxidant properties and by
doing so, hopefully improve memory [81]. Also we wanted to investigate homocysteine’s
role in altering the relationship between the neuron and the blood brain barrier and to see
if hydrogen sulfide could prevent this alternation from occurring. The reason MK801
was used was to help determine whether the NMDA receptor was indeed the receptor
orchestrating homocysteine’s negative effects on the neuron because MK801 is a known
antagonist to the NMDA receptor [82].
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As aforementioned, homocysteine has been linked numerous times to a decline in
cognitive functions both in human and animal studies. In our cognitive tests, our results
were congruent with the studies mentioned above by showing an increase in cognitive
impairment with the rise of homocysteine levels [Table 3].

Table 3: Novel object test results in terms of recognition index which is the total time spent exploring the novel object
as compared to the old one. It discerns how well the mice can determine the difference between an old memory and a
new one. Significance of Hcy was compared to the aCSF control and the treatment NaHS and MK801 are compared to
the Hcy group.

Alongside this supposed alteration of cognitive function is a marked increase of
depression which suggests a further role of homocysteine in normal brain function.
Several studies have shown correlation between elevated homocysteine and increased
occurrence of depression [77-78]. One study sampled 3,752 men aged 73 years or older
and found that higher levels of homocysteine increased the risk of depression and
lowering their homocysteine levels within normal range reduced the risk by 20% [79].
This relationship can be attributed to the anxiety of stroke and cardiovascular events
which have been known to induce depression in patients, but there seems to be a
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biochemical role outside of these psychological affects that is attributed to neurotoxicity
[79, 80]. In our mouse models we found similar results through a depression swim test
[Table 4].

Table 4: Results of the depression swim test are expressed in average seconds “floating” which is representative of
depression in mice. Significance of Hcy was compared to the aCSF control and the treatment NaHS and MK801 are
compared to the Hcy group.

The hypothesis explaining this cognitive impairment and depression by
homocysteine was based upon two routes that both summated to neurotoxicity. The first
route was through homocysteine’s effect on the blood brain barrier and its micro-vessels.
The second route homocysteine was through the neuron by its ability to induce an
excitatory ion influx by antagonizing the NMDA receptor and overexciting the
mitochondria. Our central hypothesis is shown below [Figure 5].
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Figure 5: Hypothesis for homocysteine’s interaction with the neuron ultimately leading to cognitive impairment.

The first route we examined was how homocysteine interacted with the blood
brain barrier. The blood brain barrier is a delicate system of capillaries that supplies
nutrients and proteins to the neuron. One hallmark of capillary structure is a series of
tight junctions that provide strict control of cellular transport by forming an almost
impenetrable, closely regulated zone of transport [75]. The relationship between the
capillary and the neuron is bridged by astrocytes whose primary job is to ensure the
proper delivery of nutrients and signals, as well as the expulsion of waste products [76].
These astrocytes sit just behind the endothelial lining in the basil lamina where they
branch out with end feet to create more surface area. Astrocyte end feet, termed glia
limitans, are often associated with the formation of tight junctions between the
endothelial cells and are often found in close contact [75].
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In order to understand how homocysteine was inducing its effects on micro
vessels and the blood brain barrier (BBB) a series of stress tests, slide staining, western
blots, and PcR were used to test our hypothesis. The first of these tests was a fluorometric
experiment to investigate the integrity of the BBB after the 7th day of the trial. The results
of the test confirm our hypothesis by showing an increase in permeability of the vessels
in the homocysteine group and the reduction of permeability by the NaHS group. The
results are shown below in Table 5.

Table 5: Results of blood brain barrier stress test induced by histamine vasodilation. Notice the increased permeability
of the Hcy group and the subsequent normality of the NaHS group. The increased “fuzziness” and brighter areas are
the dye leaking out of the vessels showing permeability issues.

To explain this increase of leakage we wanted to see if MMP activation played a
role in reducing vascular integrity by compromising both the basal lamina and the tight
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junctions of the micro-vessels to which the blood brain barrier is known for. To test this
we used PcR and western blotting to examine if up regulation and increased expression of
MMP occurred along with zymography, to test its activity. Also this increased leakage
was thought to interfere with the neurocoupling between the neuron and the vessels by
way of astrocyte retraction. To test this we slide stained portions of the hippocampus for
VE-Cadherin and GFAP and viewed them under a fluorescent microscope. VE-Cadherin
is used to show vessel strength and healthiness of vessel junctions (red) [83]. GFAP
stands for glial fibrillary acidic protein and is used as a marker for astrocytes (green) [84].
The results for these prospective studies are shown below in Tables 6, 7, and 8.

Table 6: The results of MMP PcR (top) and western blotting (bottom). Right is the relative increase or decrease in
expression. GFAP is shown as an indicator of proper concentrations. Note the decrease hydrogen sulfide has on MMP
expression.
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Table 7: The white arrows point to the active form of MMP-9, and the dash below signifies the activity of MMP-2. Both
activities are increased in Hcy and reduced in NaHS treatment. The MMP break down the dye and reveal light below
showing if the protein is active.

Table 8: The slide stains are of vessels in the hippocampal region. The first blue stain is DAPI for nucleus staining. The green
second column is GFAP. Take note of the astrocyte retreat into the tissue in Hcy. The red third column is VE-Cadherin
showing structural integrity of vessels and TJP. Notice Hcy’s effect on vessel integrity and NaHS revival. The last column is a
merge of the results to help show location of vessels.
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These results suggest that homocysteine is activating MMPs, which then degrade
the tight junction proteins and basal lamina of the blood brain barrier, causing a retraction
of astrocytes and an increase in permeability, thus disrupting neurocoupling causing the
link between the neuron and the vessel to be broken which agrees with our proposed
mechanism. This subsequent breaking can have negative effects for the health of the
neuron because it is starved for nutrients and believes the disruption of the blood vessels
to be an injurious event, possibly creating a neurotoxic environment where cellular waste
can compile. However the route of homocysteine through the vessels is not the only way
homocysteine can induce neurotoxicity in hippocampal neurons [85].
The second route that homocysteine can take in decreasing cognitive ability by
neurotoxicity is by acting directly on the neuron itself. This process occurs by its
interaction with the NMDA receptor [86, 87]. The NMDA receptor is a glutamate
receptor heavily involved in proper ion movement, especially in the context of calcium
importation [90]. Because of this the NMDA plays a major role in memory and learning
by long and short-term potentiation of nerve signals, it is widely considered one of the
most important receptors in the brain [90]. Homocysteine has been known to antagonize
the NMDA receptor located on the external membrane of the neuron. The opening and
increased expression of this receptor causes a massive importation of calcium into the
neuron and induces several downstream signals that affect the mitochondria. The
increased intracellular calcium excites the mitochondria causing it to release reactive
oxidative species and cytokines leading to a neurotoxic environment and possibly cell
death [88].
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To combat this excitatory effect the neuron implements mitophagy, the process of
removing mitochondria, to remove the defective “power factory” and reduce the threat of
total cell destruction [89]. One major event in our hypothesis is the stimulation of the
NMDA receptor and is why we chose MK801 to act as the negative control. Also
mitophagy and the cytotoxic release of the mitochondria induced by excitatory calcium
were important to our hypothesis [91, 92, 93]. The result of an intracellular calcium test is
shown in Table 9. The results of our PcR and western blot test to show mitophagy/
autophagy, increased release of ROS, and NMDA activation are shown in Tables 10 and
11.

Table 9: Intracellular Calcium levels measured in hippocampal regions. Notice Hcy massive increase through NMDA
antagonizing and NaHS’s apparent mitigation. Significance of Hcy related to aCSF control and Hcy+ NaHS related to
Hcy.

Kyles 31

Table 10: Semi Quantitative PcR results: LC3 is an autophagy marker and its up-regulation is indicative of neuronal
mitochondrial destruction. NOX2 marks for NADPH oxidase and reactive oxidative species. SOD2 marks
mitochondrial superoxide dismutase which is active in removing reactive oxidative species. P62 is an autophagy
marker whose decrease is indicative of autophagic occurrences. GAPDH is baseline for loading.

Table 11: Western Blot Results: NR1 is a subunit of the NMDA receptor whose increase in Hcy in concurrent with its
excitatory effects; NaHS treatment reduces increase. P62 is an autophagy marker whose decrease is indicative of
autophagic occurrences. SOD2 marks mitochondrial superoxide dismutase which is active in removing reactive
oxidative species. GAPDH is loading concentrations for baseline.

These results help to confirm our hypothesis. The increased level of intracellular
calcium is a hallmark of antagonizing the NMDA receptor. This increase of calcium can
alter synaptic function and lead to improper signaling which ultimately affects the proper
formation of memories [93]. We confirm the antagonization with NR1 which is a subunit
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of the NMDA receptor. NR1’s increase in expression is indicative of its excitation [91].
The increased expression of autophagy and mitochondrial dismutase markers is a sign of
neurotoxicity as well as mitochondrial damage [91, 92]. Also in our experiment we found
that ATP concentrations in the hippocampal regions were significantly decreased in the
homocysteine treatment group as compared to the control. This decrease in ATP is yet
another indicator that the neuron’s internal environment is being affected by the influx of
calcium as well as the broken neurocoupling between the vessels.

VI: Conclusion:
Homocysteine’s wide range of negative effects gives rise to its involvement in the
possible pathologies of several systems. Ever increasing research on this molecule is
finding implications in numerous diseased states and the mechanisms controlling them. In
terms of the vascular system however, homocysteine’s effects on endothelial cells seems
to be quite detrimental by simulating an injurious environment, but a great deal of
research still needs to be done to elucidate the key molecular players and major routes of
action. This increase in vascular stress can induce a myriad of complications ranging
from stroke and atherosclerosis to coronary heart failure and degradation of the neuronal
microvessels. In the nervous system, specifically the neurons of the hippocampus,
homocysteine’s effects follow the route of excitatory theory by antagonizing the NMDA
receptor causing an increased occurrence of mitophagy and autophagy by way of calcium
importation. The degradation of mitochondria and generation of reactive oxidative
species paired with the altercation of the delicate astrocyte connection to the microvessels
provides a suitable mechanism of cognitive decline by means of neurotoxicity.
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All in all the control of homocysteine levels in one’s life can be easily
accomplished by practicing a balanced diet with regular exercise. The simple addition of
B vitamins and folic acid to diets have been shown to significantly reduce the onset of
several vascular issues as well as to lower blood concentrations of homocysteine. Garlic
and its stimulation of hydrogen sulfide production has also been shown to mediate
homocysteine’s negative effects within the brain by inducing glutathione production and
mediating the NMDA receptor [94]. From the broad range and sharp increase of
homocysteine research, it seems as if it will play a much bigger role in the future of
medicine, and may someday pass cholesterol as a biomarker for general vascular health.
Keeping an eye on homocysteine would be a wise decision for students entering the
medical profession and the continuation of its research is sure to produce some
fascinating results.
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